Candel Therapeutics, Inc.

Dr. Paul-Peter  Tak FOCIS, M.D., Ph.D.

President, Chief Executive Officer & Director

Dr. Seshu  Tyagarajan Ph.D.

Chief Technical & Development Officer

Dr. William Garrett Nichols M.D., M.S.

Chief Medical Officer

Ms. Susan  Stewart J.D., L.L.M.

Chief Regulatory Officer

Mr. Charles  Schoch

Interim Chief Financial Officer, Principal Accounting Officer, Treasurer & Secretary

Dr. Francesca  Barone M.D., Ph.D.

Chief Scientific Officer

Ms. Ileen B. Winick

Chief People Officer

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Candel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachusetts-based company released promising results from its Phase 3 clinical trial for CAN-2409, its experimental immunotherapy for localized prostate cancer.

Candel Therapeutics rides high on promising Phase 3 data, funding boost

Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of common stock at $6 per share and pre-funded warrants for 3.3 million shares at $5.99 per warrant, allowing buyers to acquire shares at an exercise price of $0.01 each.

Candel Therapeutics raises $92M in public offering following prostate cancer trial success

NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the closing of its previously announced underwritten public offering of 12,000,001 shares of its common stock at a price to the public of $6.00 per share and pre-funded warrants to purchase up to an aggregate of 3,333,333 shares of its common stock at a price to the public of $5.99 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The 12,000,001 shares of common stock sold in the offering include 2,000,000 shares sold pursuant to the full exercise of the underwriters' option to purchase up to 2,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday.

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering of its common stock and pre-funded warrants. The offering includes approximately 10 million shares of common stock at $6 per share and approximately 3.33 million pre-funded warrants priced at $5.99 each, representing the public offering price minus a $0.01 per share exercise cost.

Candel Therapeutics, Inc.CADL

Candel Therapeutics, Inc.
CADL